Stock Under $10 with 50-100% upside potential - 14 Days FREE!

8 More ETFs Join Deathwatch in December

Stock quotes in this article: MFSA, DFVL, GIVE, ALFA, CSMB, CVOL, RYF, EDEN, CHEP, MDYV, CURE, BLND, DCNG, DVYA, ECNS, UPV, NOMO, BTAH, QLT 

NEW YORK (TheStreet) -- Eight new names are joining ETF Deathwatch for December, and nine products are coming off the list.

Six are leaving due to increased investor interest, and three ETFs are exiting because they are now dead, delisted, and liquidated. ETF Deathwatch now consists of 374 (274 ETFs and 100 ETNs) names from the 1,445 listed for trading.

Even though there is a risk these exchange-traded products (ETPs) could eventually close, liquidity risk is present today. For example, the iPath US Treasury 5-Year Yield Bull (DFVL) hasn't traded since Sept. 13. It is just one of eight Zombie products going the entire month of November with zero volume.

iPath Short Enhanced MSCI EAFE (MFSA) is quoted Friday with a bid price of $37.14 and an ask of $112.10 (a spread of $74.96). Even more troubling is the fact that there are only 100 shares available at each end of those extremes.

The average product on ETF Deathwatch is more than 31 months old and has $6.3 million in assets. Sponsor patience varies widely, with some closing non-profitable products within their first year while others seem willing to subsidize products forever.

There are currently 44 exchange-traded funds and exchanged-traded notes on the list that have been on the market for more than five years. The quantity of funds with less than $2 million in assets stands at 60.

The complete list of 374 products on ETF Deathwatch for December 2012 can be found here.

The ETPs added to ETF Deathwatch for December:

    1. AdvisorShares Global Echo ETF (GIVE)

    2. AlphaClone Alternative Alpha ETF (ALFA)

    3. Credit Suisse Merger Arbitrage Liquid 2x Monthly ETN (CSMB)

    4. C-Tracks Citi Volatility Index Total Return ETN (CVOL)

    5. Guggenheim S&P Equal Weight Financials (RYF)

    6. iShares MSCI Denmark Capped Investable Market (EDEN)

    7. QuantShares U.S. Market Neutral Value (CHEP)

    8. SPDR S&P 400 Mid Cap Value ETF (MDYV)





The ETPs removed from ETF Deathwatch due to improved health:

    1. Direxion Daily Healthcare Bull 3x (CURE)

    2. ETRACS DJ-UBS Commodity 2-4-6 Blended Futures ETN (BLND)

    3. iPath Seasonal Natural Gas ETN (DCNG)

    4. iShares Asia/Pacific Dividend 30 (DVYA)

    5. iShares MSCI China Small Cap Index Fund (ECNS)

    6. ProShares Ultra MSCI Europe (UPV)

The ETPs removed from ETF Deathwatch due to death and delisting:

    1. QuantShares U.S. Market Neutral Anti-Momentum (NOMO)

    2. QuantShares U.S. Market Neutral High Beta (BTAH)

    3. QuantShares U.S. Market Neutral Quality (QLT)

At the time of publication the author had no position in any of the stocks mentioned.

This article was written by an independent contributor, separate from TheStreet's regular news coverage.

Ron Rowland is the founder and president of Capital Cities Asset Management, a fee-based registered investment adviser in Austin, Texas. He is also the founder and publisher of Invest With An Edge and All Star Investor, where he has been providing market commentary and active investment advice since 1991. Opinions expressed in this article should not be considered personal recommendations to buy or sell any security.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,303.10 8.60 0.06%
NASDAQ 3,459.14 -0.28 -0.01%
S&P 500 1,649.60 -0.91 -0.06%
US 10 Yr 2.011% -0.012

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs